Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis response

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis response

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201): Novartis response
07 March 2013
(199.24 Kb 58 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 01 March 2013